Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response.

MLA

Wauben, M. H., et al. “Inhibition of Experimental Autoimmune Myasthenia Gravis by Major Histocompatibility Complex Class II Competitor Peptides Results Not Only in a Suppressed but Also in an Altered Immune Response.” European Journal of Immunology, vol. 26, no. 12, Dec. 1996, pp. 2866–75. EBSCOhost, https://doi.org/10.1002/eji.1830261210.

APA

Wauben, M. H., Hoedemaekers, A. C., Graus, Y. M., Wagenaar, J. P., van Eden, W., & de Baets, M. H. (1996). Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response. European Journal of Immunology, 26(12), 2866–2875. https://doi.org/10.1002/eji.1830261210

Chicago

Wauben, M H, A C Hoedemaekers, Y M Graus, J P Wagenaar, W van Eden, and M H de Baets. 1996. “Inhibition of Experimental Autoimmune Myasthenia Gravis by Major Histocompatibility Complex Class II Competitor Peptides Results Not Only in a Suppressed but Also in an Altered Immune Response.” European Journal of Immunology 26 (12): 2866–75. doi:10.1002/eji.1830261210.